Kurian Deepthi Elizabeth, Kalra Sanjay, Kapoor Nitin
Department of Ophthalmology, Schell eye hospital, Christian Medical College, Vellore ,India.
CEO & Co-Founder, Fitterfly-Digital Health & Therapeutics, India.
J Pak Med Assoc. 2022 Apr;72(4):767-770. doi: 10.47391/JPMA.22-28.
Graves' orbitopathy or thyroid associated orbitopathy (TAO) is a disquieting condition both for the patient and the clinician. While the mainstay of treatment of the orbitopathy is corticosteroids, its action is non-specific. The arguments against its use also include multiple side effects and recurrence on stopping it. While some clinicians are complacent with the drug due to our long term experience with it, many are in search for specific so called 'targeted' treatment. The autoimmune process in TAO is rather complex where multiple cytokines act at more than one level making it challenging to control the inflammation. Hence, in order to discover better treatment strategies, having a sound understanding of the pathogenesis of the disease is essential.
格雷夫斯眼眶病或甲状腺相关性眼眶病（TAO）对患者和临床医生来说都是令人不安的病症。虽然眼眶病治疗的主要手段是皮质类固醇，但其作用是非特异性的。反对使用它的理由还包括多种副作用以及停药后复发。虽然一些临床医生因长期使用该药而对此感到安心，但许多人正在寻找所谓的特定“靶向”治疗方法。TAO中的自身免疫过程相当复杂，多种细胞因子在多个层面发挥作用，这使得控制炎症具有挑战性。因此，为了发现更好的治疗策略，深入了解该疾病的发病机制至关重要。
